Polycomb-group proteins in the initiation and progression of cancer
Polycomb-group proteins in the initiation and progression of cancer
复制标题
多梳蛋白在癌症发生和进展中的作用
DOI：
10.1016/j.jgg.2021.03.013
复制
发表时间：
2021
影响因子：
5.9
通讯作者：
Wu Xudong
中科院分区：
文献类型：
--
作者：
Zhao Xiujuan;Wu Xudong
Polycomb组（PcG）蛋白是染色质调节剂家族，并且对于维持细胞身份至关重要。PcG机制可以分为至少三种多蛋白复合物，即多梳抑制复合物1（PRC 1）、PRC 2和多梳抑制性去泛素酶（PR-DUB）。它们的失调与人类癌症的发生和发展有关。在这里，我们回顾了PcG蛋白在转录调控和DNA损伤修复中的最新认识，并强调了与癌症标志的联系。因此，我们讨论了一些药物开发或策略的最新进展，对癌症所造成的增益或损失的PcG功能。
The Polycomb group (PcG) proteins are a family of chromatin regulators and critical for the maintenance of cellular identity. The PcG machinery can be categorized into at least three multi-protein complexes, namely Polycomb Repressive Complex 1 (PRC1), PRC2, and Polycomb Repressive DeUBiquitinase (PR-DUB). Their deregulation has been associated with human cancer initiation and progression. Here we review the updated understanding for PcG proteins in transcription regulation and DNA damage repair and highlight increasing links to the hallmarks in cancer. Accordingly, we discuss some of the recent advances in drug development or strategies against cancers caused by the gain or loss of PcG functions.